



Published in final edited form as:

*Am J Reprod Immunol.* 2023 September ; 90(3): e13768. doi:10.1111/aji.13768.

## Tryptophan metabolism and immune alterations in pregnant Hispanic women with chronic *Toxoplasma gondii* infection

Stephanie Prescott<sup>1,2</sup>, Tina Mutka<sup>1</sup>, Kelley Baumgartel<sup>1</sup>, Ji Youn Yoo<sup>6</sup>, Hailey Morgan<sup>1</sup>, Teodor T. Postolache<sup>3</sup>, Andreas Seyfang<sup>2</sup>, Johanna M. Gostner<sup>4</sup>, Dietmar Fuchs<sup>5</sup>, Kami Kim<sup>2</sup>, Maureen E. Groer<sup>6</sup>

<sup>1</sup>University of South Florida College of Nursing, Tampa, FL.

<sup>2</sup>University of South Florida Morsani College of Medicine, Tampa, FL

<sup>3</sup>Department of Psychiatry, University of Maryland School of Medicine; Rocky Mountain MIRECC for Suicide Prevention, Aurora, Colorado; VISN 5 MIRECC, Baltimore, MD

<sup>4</sup>Institute of Medical Biochemistry, Medical University of Innsbruck, Austria

<sup>5</sup>Institute of Biological Chemistry, Medical University of Innsbruck, Austria

<sup>6</sup>University of Tennessee College of Nursing, Knoxville, TN

### Abstract

Pregnancy markedly modifies women's metabolism and immune functions. We hypothesized that pregnancy might alter the immune and metabolic responses to chronic *T. gondii* infection in pregnancy. A population of 690 pregnant Hispanic women were screened for antibodies to *T. gondii* and 158 women were positive (22% positivity) with 83% showing high avidity indices. These seropositive women were followed through their pregnancies with 4 data collection time points and a postpartum collection at two clinics in Tampa, Florida. A *T. gondii* seronegative group (N=131) was randomly selected to serve as a control group and measured along pregnancy in the same way. Serum levels of tryptophan, kynurenine, and their ratio, phenylalanine, tyrosine and their ratio, neopterin and nitrite were measured through pregnancy and the postpartum. A plasma cytokine panel (IFN- $\gamma$ , TNF $\alpha$ , IL-2, IL-10, IL-12, IL-6, IL-17) was analyzed in parallel. The major findings suggest that indoleamine 2,3-dioxygenase (IDO-1) was less activated in *T. gondii* seropositive pregnant Hispanic women with chronic infection. Evidence for IDO-1 suppression was that tryptophan catabolism was less pronounced and there were lower levels

---

Contacts: Dr. Maureen Groer, University of Tennessee College of Nursing, 1214 Circle Park Drive, Knoxville, TN 37996, mgroer@utk.edu, 865-406-7325.

Author Contributions:

Conceptualization of study and funding acquisition: M.G., A.S., T.P.;

Data acquisition: T.M., M.G., A.S., J.Y.Y

Data Analysis and Interpretation: M.G., S.P.

Writing the manuscript: M.G., S.P.

Providing review and critiques of the manuscript: K.B., H.M., J.G., D. F., K.K., T.P., A.S., J.Y.Y.

Ethics statement: The authors confirm that the ethical policies of the journal, as noted on the journal's author guidelines page, have been adhered to and the appropriate ethical review committee approval has been received. The study conformed to the US Federal Policy for the Protection of Human Subjects.

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions

of multiple inflammatory cytokines including IFN- $\gamma$ , which is the major inducer of IDO-1, and higher nitrite concentration, a surrogate marker for nitric oxide, an inhibitor of IDO. In contrast, TNF- $\alpha$  increased over time in the *T. gondii* positive women. We also observed lower titers of *T. gondii* IgG across pregnancy compared to the postpartum, suggesting that immune suppression in pregnancy differs from the postpartum period of chronically infected women.

## Keywords

*Toxoplasma gondii*; pregnancy pathway chronic infection; immunity; tryptophan pathway

---

## Introduction

### *Toxoplasma gondii* Infection

*Toxoplasma gondii* (*T. gondii*) is a highly successful parasite, infecting about a third of the world population (Montoya & Liesenfeld, 2004), yet is still considered a neglected parasitic infection by the Centers for Disease Control (CDC). *T. gondii* is considered “neglected” due to its association with poverty, its high prevalence, despite its significant pathological effects (Hotez, 2014). It is well known that acute infection during pregnancy increases the risk of miscarriage and is associated with damage to multiple organs in the fetus (i.e., congenital toxoplasmosis) (Dubey et al., 2021). After the acute phase of infection, the parasite persists as a chronic, lifelong infection that is associated with the development of intracellular cysts containing the bradyzoite form of the parasite in immune privileged sites such as the eyes, the brain and heart muscle (Xiao & Yolken, 2015). Chronic *T. gondii* infection during pregnancy is generally regarded as having no obstetrical risk, although reactivation has been reported in pregnant women with severe immunocompromise such as HIV disease (Kodym et al., 2015).

There is a vigorous microglial, innate and Th-1 polarized CD8<sup>+</sup> T-cell dependent immune response to this parasite during both the acute and chronic phases of infection. The innate immune response involves toll like receptors (TLRs) and other pathogen recognition receptors on macrophages and dendritic cells (DCs). IL-12 production and antiparasitic action, including phagocytosis, against the parasite by these activated innate antigen presenting cells ensues and can result in the death of infected cells (Sasai et al., 2018). Most infected individuals retain a persistent lifelong chronic infection of intracellular cysts containing bradyzoites, the dormant form of the parasite. Cells of the adaptive immune system patrol cysts and directly kill parasites that leak from the cysts or secrete antibodies to keep the infection under control and essentially asymptomatic. Throughout the life of the host, immunoglobulins against various *T. gondii* antigens are produced, and in general IgG titer and avidity indices rise with aging, suggesting that there is some exit of bradyzoites from cysts constantly stimulating B cell defenses (Roiko et al., 2018) (Weilhammer et al., 2012). IFN- $\gamma$  is released during acute infection largely through CD4<sup>+</sup> T cells and Natural Killer (NK) cells, but CD8<sup>+</sup> T cells are the major effectors during chronic infection by secreting perforin to rupture and destroy cysts directly (Suzuki, 2021), and by releasing IFN- $\gamma$  and thus preventing reactivation of acute infection from the leak of bradyzoites from cysts. CD4<sup>+</sup> cells help the vigorous CD8<sup>+</sup> effector response through Th-1 cytokine release.

IFN- $\gamma$ , along with other proinflammatory cytokines, such as IL-1 $\beta$ , IL-6, IL-18 and tumor necrosis factor alpha (TNF- $\alpha$ ), induce indoleamine 2,3-dioxygenase-1 (IDO-1) expression (Duan et al., 2018). IDO-1 and TDO (tryptophan 2,3-dioxygenase) are enzymes that catabolize tryptophan into kynurenine, and other downstream catabolites (see Figure 1). TDO is found in the liver and placenta and is activated by corticosteroids, while IDO-1 is ubiquitous, and present in many types of cells. (Sedlmayr et al., 2014) Shunting of tryptophan into the kynurenine pathway by both pathways is thought to play a large protective role in infection, perhaps by decreasing the availability of this amino acid that is essential for invading microbes, as well as increasing downstream kynurenine metabolites which are immunosuppressive during pregnancy (Tatsumi et al., 2000) as well as in other conditions such as autoimmune disease and cancer (Hjortsø et al., 2015). Tryptophan is an amino acid required by many cells, and is required for *T. gondii* parasite growth (Pfefferkorn et al., 1986). The multiple functions of tryptophan and the tryptophan catabolite pathway in pregnancy appear to be protective. The placenta also produces TDO and IDO-1 and the role for tryptophan depletion and catabolite production during pregnancy is thought to be immunosuppression of T-cells and macrophages, thereby protecting against maternal immune attack on semi-allogeneic fetal tissues (Munn et al., 1998) (Kudo et al., 2004) (Silvano et al., 2021). Tryptophan levels decrease throughout the course of pregnancy, but there is controversy as to why this occurs. The decline could be related to the increasing metabolic demand by the mother and the fetus for protein synthesis or the result of accelerated breakdown resulting from the inflammation associated with pregnancy. However, it may be that the decline is in albumin-bound tryptophan and free tryptophan is actually increased in pregnancy (Badawy, 2015).

## Pregnancy

There is much evidence that chronic *T. gondii* can reactivate in states of immune suppression, such as in HIV disease. (Manuel et al., 2020). It is reasonable to suggest that the normal immune suppression seen during pregnancy might impede the immune response to chronic *T. gondii* infection and lead to reactivation (Rezende-Oliveira et al., 2020). A recent systematic review of association of miscarriage with *T. gondii* IgG seroprevalence in cross-sectional and case-control studies showed a pooled odds ratio of 1.65 (95% CI: 1.31–2.09) and 2.26 (95% CI: 1.56–3.28) (Nayeri et al., 2020). It is likely that chronic infection and possibly reactivation occurred in these pregnant women. The co-occurrence of chronic *T. gondii* infection and pregnancy may alter immunologic and metabolic states as host metabolism such as the tryptophan kynurenine pathway, or nitric oxide metabolism, plays a role in reactivation (Weilhammer et al., 2012). The immune system in pregnancy promotes maternal-fetal tolerance but may threaten cell-mediated containment of bradyzoites within chronic *T. gondii* cysts. The old concept of a Th-1/Th2 negative skew is simplistic and has been replaced with models that show a strong T regulatory (Treg) bias in pregnancy, associated with Th-1 and Th-17 suppression or a Th-17/Treg balance (Moldenhauer et al., 2022). Tregs recruited from maternal blood to the fetal-maternal interface secrete anti-inflammatory cytokines such as TGF- $\beta$  and IL-10 at the decidua upon implantation, and induce peripheral antigen presenting cells to secrete reduced amounts of IFN- $\gamma$  and TNF- $\alpha$ , and higher levels of IL-4, IL-5, and IL-10 (Piccinni et al., 2021). Pregnancy induced changes

in immune tolerance may therefore potentially interfere with the dominant Th-1 and Treg homeostatic mechanisms that normally restrain cysts from producing and releasing *T. gondii* bradyzoites.

The current study was a large prospective examination of *T.gondii* seropositive compared to seronegative pregnant Hispanic women, chosen for their vulnerability to chronic infection with the parasite (Pappas et al., 2009). We sought to characterize the course of chronic *T. gondii* infection in pregnancy and hypothesized that chronic *T. gondii* infection could reactivate during pregnancy and would be associated with alterations in immunity and tryptophan catabolism. We evaluated this possibility through serial retinoscopy, PCR, *T. gondii* IgG and IgM titers, serotypes, avidity, and plasma levels of tryptophan, kynurenine, and their ratio, phenylalanine, tyrosine and their ratio, neopterin and nitrite and a plasma cytokine panel (IFN $\gamma$ , TNF $\alpha$ , IL-2, IL-10, IL-12, IL-6, IL-17), measured throughout the pregnancy and once in the postpartum.

## Methods

The USF Institutional Review Board approved the study, and all women gave written informed consent. Pregnant women who self-identified as Hispanic were recruited in two prenatal clinics in Tampa, Florida. Exclusion criteria included age under 18 years old, HIV infection, drug and/or alcohol dependency, autoimmune disease or cancer, steroid medications, BMI<20, plans to terminate the pregnancy, or presence of congenital anomalies. All screened women (N=690) provided a 15 mL venous blood sample at the first prenatal visit (usually first trimester). Blood was collected in tubes with EDTA as anticoagulant and were kept cold until brought to lab for processing. Plasma was extracted and aliquots stored at -80°C. IgG titers to *T. gondii* (IU/mL) were measured with the *Toxoplasma gondii* IgG ELISA kit (Cat. No. IB79841, IBL America) following the manufacturer's instructions with a cutoff of 10 IU/ml. A seronegative control group (N=124) was randomly selected from the sample at the first prenatal visit and followed through pregnancy. All seropositive women (N=158) were enrolled and quantitative IgG titers, as well as the cytokine and metabolites were measured in as many as 4 pregnancy visits and once in the postpartum. The data were divided into first trimester (3-12 weeks), early (13-18 weeks) and late (19-23 weeks) second trimester, and early (24-30 weeks) and late (31-42 weeks) third trimester. In cases where 2 visits occurred in the same interval, the data were averaged. The sample size having blood draws was 178 at the first trimester visit women, 236 for the late second trimester, 227 for the late third trimester and 202 for the postpartum visit.

*T. gondii* serotypes (Types I/II, II, atypical, and non-reactive) were analyzed with a peptide-based ELISA assay adapted from Kong et al. (Kong et al., 2003) and Shobab et al. (Shobab et al., 2013). An avidity ELISA was performed on all plasma samples from *T. gondii* seropositive women, using a kit from Euroimmun (Lubeck, Germany), following kit instructions, to determine if any primary infections were present in the sample and to estimate duration of chronic infection. Results were grouped as low avidity, borderline avidity and high avidity. To determine serotype, *T. gondii* positive IgG serum samples were tested for reactivity against GRA6 and GRA7 strain-specific allelic peptide motifs (Kong et

al., 2003; Shobab et al., 2013). Each serotyping ELISA contained three *T. gondii* negative control sera (*T. gondii* IgG levels of less than 2 IU/mL) for calculation of the threshold values for each serotype, i.e., above which normalized assay values were positive. Threshold values were determined for each serotype-specific peptide by averaging the optical density (OD) values of the three normalized *T. gondii* negative samples and then adding two standard deviations (Shobab et al., 2013).

## Reactivation

We assessed *T. gondii* reactivation in women with positive titers at each visit. First, we used a Digital Retinopathy System (DRS)-equipped retinoscope camera (ICare, Revenio Group, Finland) to capture digital retinal images at each study visit. A consulting ophthalmologist examined the retinal images for the characteristic retinochoroiditis or scars associated with *T. gondii*. Next, we spot checked IgM levels by ELISA (IBL) in 75 samples, and *T. gondii* DNA in 18 cord bloods and 20 postpartum samples using qPCR. The Toxoplasma ELITe MGB assay (ELITechGroup, France) was performed according to manufacturer's instructions with a Bio-Rad real-time PCR system. We used the *T. gondii* RH repeat region for designing the primers (F; 5'-AGA GAG ACC GGA ATG CGA TCT-3', R; 5'-TTC GTC CAA GCC TCC GAC T-3') and probe-fam (5'-FAM-TCG TGG TGA TGG CGG AGA GAA TTG A-3') from Invitrogen (Waltham, MA).

Plasma aliquots were kept frozen at  $-80^{\circ}\text{C}$  until analysis. Tryptophan, kynurenine, phenylalanine, tyrosine, neopterin and nitrite were measured in all samples from each visit. Amino acids and the derivate kynurenine were analyzed using high-performance liquid chromatography (HPLC)-based methods as reported earlier (Geisler et al., 2015). In brief, 3-nitro-L-tyrosine was added as internal standard and plasma samples were deproteinized with trichloroacetic acid. Separation was performed on a reversed-phase LiChroCART 55-4 C18 column (3  $\mu\text{m}$  particle size, Merck, Darmstadt, Germany) using sodium acetate buffer (15 mmol/L, pH 4.0) for analysis of tryptophan and kynurenine, or potassium dihydrogen phosphate (0.015 mol/L) for analysis of phenylalanine and tyrosine on a Varian ProStar liquid chromatography system with autosampler Model 400 (Varian, Palo Alto, CA). Kynurenine was monitored by its ultraviolet light-absorption at 360 nm (UV-detector SPD-6A, Shimadzu, Japan) and tryptophan by detection of its natural fluorescence at 286 nm excitation and 366 nm emission wavelengths (ProStar fluorescence-detector Model 360, Varian). Peaks were identified by comparing peak retention time to an albumin-based calibrators. Neopterin levels were measured by enzyme-linked immunoassay (BRAHMS, Hennigsdorf, Germany) according to the manufacturer's instructions, with a detection limit of 2 nmol/L. Nitrite concentrations were measured with the modified Griess-Ilosvay diazotization reaction assay (Merck KGaA, Darmstadt, Germany) as reported previously (Geisler et al., 2015).

## Cytokines

Cytokines (IFN- $\gamma$ , TNF $\alpha$ , IL-2, IL-6, IL-10, IL-12, IL-17) were measured in plasma aliquots in duplicate using the Luminex MagPix multiplexing system. Coefficients of

variation were under 10, and cytokines that measured below the limit of detection (LOD) were assigned a value between zero and the LOD.

## Demographics

An investigator-developed questionnaire available in Spanish and English was used to collect data on age, parity, number of people living in the household, country of origin, time in the US, health problems, medications, smoking and drinking habits, income, occupation, and education. This information was updated as needed over the course of the pregnancy. Access to the electronic medical record was also used for additional health related data collection.

## Statistics

SPSS 28 was used for demographic analysis and GraphPad Prism version 9.5.0 for Mac OS 13.0, GraphPad Software, San Diego, California USA, [www.graphpad.com](http://www.graphpad.com), was used for immunoglobulins, metabolites, and cytokines. Robust nonlinear regression and false discovery rate (ROUT,  $q=1\%$ ) was used to detect significant outliers at each time point for each dataset. (Motulsky & Brown, 2006). After outlier removal, mixed effects models were fitted with Geisser-Greenhouse correction for non-sphericity (Bathke et al., 2009), if required, to examine relationship across time for the tryptophan, inflammation biomarkers (neopterin, nitrite, kynurenine), immunoglobulins, and proinflammatory and anti-inflammatory cytokines by *T. gondii* seropositivity status. Multiple comparisons were controlled for false discovery using the original Benjamini and Hochberg method with a desired false discovery rate of  $< 0.1$  (Bathke et al., 2009). Country of birth and age were included in these models initially as covariates using SPSS, version 28, as *T. gondii* positivity was different by these variables (see Table 1), but controlling for these variables had no effect on the results. Interaction terms were excluded from the models as only one variable had an interaction with *T. gondii* status and time.

## Results

### Demographics

The population under study consisted of women who self-identified as Hispanic. Most of these women were immigrants, having been born in countries or territories outside of mainland US. The more common origins were Mexico, Puerto Rico, Cuba, and Honduras. These women were receiving prenatal care in clinics for socioeconomically deprived populations. Many women spoke only Spanish and were in families with members employed as agricultural workers in Florida. The women had an average number of 2 children, with a range from 0 to 8. Demographic details comparing the *T. gondii* seropositive to seronegative group are shown in Table 1. The incidence of seropositivity was 22% in the population in contrast to the seroprevalence of the U.S. national population, which the CDC reports as 11% (<https://www.cdc.gov/parasites/toxoplasmosis/epi.htm>).



## Toxoplasma Reactivation

Only one *T. gondii* ocular lesion in the 158 *T. gondii* positive women was found, indicating previous chorioretinitis scarring. There was no evidence by PCR of *T. gondii* DNA in any of the random plasma samples (N=38).

## Titers, Avidity and Serotypes

One sample from 75 randomly selected plasma samples had a positive IgM along with IgG to *T. gondii*, and the IgM declined at the next study visit, suggesting that she did not have acute infection, so her data were retained. IgG titers in *T. gondii* positive women were lower during pregnancy compared to postpartum titers. The mean avidity index (A.I.) was  $82.2 \pm 2.79$ , and range was between 37.4 and 373. The majority (88.2%) of the women had high A.I. (>60), 11.1% had borderline A.I. (50-60), and only 1 (0.06 %) had low A.I. (<50). The distribution of serotypes across the Hispanic *T. gondii* positive women showed that the atypical (25%) and the non-reactive (40%) serotypes were the most prevalent in those born outside the U.S., while the U.S.-born *T. gondii* positive women had an equal distribution of the 4 known *T. gondii* serotypes. There were differences by both IgG titers and avidity indices by serotype, with the atypical serotype showing both highest titer and avidity. This was not statistically significant.

## Tryptophan and Inflammation Biomarkers

The drop in tryptophan levels over pregnancy in all women was highly significant ( $F=39.96$ ,  $p<0.001$ ) and tryptophan was significantly higher across pregnancy in the *T. gondii* seropositive women ( $F=7.97$ ,  $p<0.005$ ) (Figure 2). The ratio of kynurenine to tryptophan rose over pregnancy ( $F=62.31$ ,  $p<0.001$ ) but *T. gondii* seropositive women had lower ratios ( $F=3.81$ ,  $p=0.052$ ) (Figure 3). Neopterin also rose significantly throughout pregnancy ( $F=32.28$ ,  $p<0.001$ ), but did not differ in women with *T. gondii* (data not shown). Nitrite rose in both groups through pregnancy ( $F=9.473$ ,  $p<0.001$ ) and was significantly higher across time in the *T. gondii* positive group ( $F=6.057$ ,  $p=0.0015$ ) (Figure 4). Phenylalanine and tyrosine both differed across pregnancy but did not show any differences by *T. gondii* status (data not shown).

## Cytokines

Tested cytokines varied significantly over time throughout pregnancy (some rising, some falling) and several inflammatory cytokines were significantly lower in the *T. gondii* positive group, IFN- $\gamma$  over time ( $F=3.51$ ,  $p=0.005$ ), by *T. gondii* status ( $F=0.68$ ,  $p<0.001$ ) (Figure 5a); IL-6 over time ( $F=14.45$ ,  $p<0.001$ ), by *T. gondii* status ( $F=14.86$ ,  $p=0.02$ ) (Figure 5b); IL-17 over time ( $F=9.8$ ,  $p<0.001$ ), by *T. gondii* status ( $F=10.21$ ,  $p=0.0016$ ) (Figure 5c); and IL-12 over time ( $F=8.406$ ,  $p<0.001$ ), by *T. gondii* status ( $F=10.7$ ,  $p=0.0012$ ) (Figure 5d). The interaction of time and *T. gondii* status was only significant in IL-12 ( $F=6.236$ ,  $p<0.001$ ) (Figure 5e). IL-12 varied significantly over time ( $F=8.406$ ,  $p<0.001$ , and was lower in *T. gondii* women  $F=10.7$ ,  $p=0.0012$ ). IL-10 did not differ significantly across pregnancy or by *T. gondii* serostatus (data not shown). TNF- $\alpha$ , however, showed significant increases across time ( $F=9.685$ ,  $p<0.001$ , and by *T. gondii* status ( $F=7.44$ ,  $p=0.007$ ) (Figure 5f).

## Discussion

In our prospective sample, we confirmed the presence of chronic infection through avidity titers and absence of IgM. We saw no evidence of *T. gondii* reactivation in these chronically infected pregnant women by PCR or retinoscopy. While IgG titers were lower during pregnancy compared to postpartum levels, titers alone may not reflect parasite burden and serological titers are not considered a surrogate of clinical disease (Beazley & Egerman, 1998). Antigen stimulation leading to elevation of the IgG titers may occur in the presence of tachyzoites or bradyzoites (Deshmukh et al., 2021). The bradyzoite cysts were, until recently, considered immunologically silent during chronic infection but recent study in animal models suggest that the cysts are more dynamic and CD8<sup>+</sup> T cells are capable of cyst destruction even during the chronic phase (Suzuki, 2021). This model also suggests that the constant CD4<sup>+</sup> and memory CD8<sup>+</sup> T cell recruitment and activation in chronic infection produces a mild but constant reactivation of the Th-1 axis leading to T cell exhaustion (Khan & Moretto, 2022).

*T. gondii* serotype is known to be associated with virulence, and the most common serotypes in our sample were the atypical and nonreactive types. There was both higher IgG titer and avidity index in those with the atypical serotype, and this serotype is considered more virulent than the more common Type II. The non-reactive (NR) serotype prevalence in this Hispanic population is a novel finding that mimics previous studies (de-la-Torre et al., 2013; Shobab et al., 2013). It was reported in sera from ocular toxoplasmosis patients in Columbia (de-la-Torre et al., 2013). Individuals with NR serotype (43%) were also observed in a study of German patients with ocular toxoplasmosis (Shobab et al., 2013). The NR serotype may have a genetic background as it represents the inability to react to archetypal *T. gondii* allelic peptide motifs. It may also be that the nonreactivity may indicate suppression of the antibody response to less abundant serotype-specific antigens. The roles of serotypes in adverse pregnancy events deserves further study.

In exploring the relationships among tryptophan metabolites, inflammatory biomarkers, cytokines, and the IDO-1 pathway, we found lower levels of many inflammatory cytokines including IFN- $\gamma$ , a key cytokine in *T. gondii* parasite control. There was evidence of reduced activation of the IDO-1 pathway, which is normally activated by IFN- $\gamma$ , with corresponding higher tryptophan levels and lower kynurenine/tryptophan ratios in the seropositive women, and higher levels of nitrite, a proxy for NO, which inhibits IDO-1, and subsequent immunomodulation by the parasite that can result in suppression of *Toxoplasma*-directed antibody response (Saeij et al., 2007). Our findings of reduced levels of certain Th-1 and proinflammatory cytokines (IFN- $\gamma$ , IL-17, IL-12, IL-6) either throughout pregnancy or at certain times during pregnancy suggest that T cell function in chronically infected pregnant women may be altered. Throughout the life of the chronically infected host there is an equilibrium between the parasite survival and the Th-1, Th2, Th-17, and T regulatory (Treg) host responses to the parasite (Sana et al., 2022). Maintenance of quiescence involves a balance between pro- and anti-inflammatory cytokines. Overproduction of proinflammatory cytokines, such as IFN- $\gamma$  could be harmful to the host but is balanced by anti-inflammatory cytokines, such as IL-10, produced by T regs. *T. gondii* bradyzoites can evade host immune effects by suppressing IFN- $\gamma$  signaling (Zimmermann et al., 2006),



blocking STAT-1 mediated transcription of inflammatory cytokines (Lima & Lodoen, 2019), reducing NF- $\kappa$ B signaling (Shapira et al., 2004) and producing effector molecules such as granule proteins which mediate iNOS expression and nitric oxide thereby reducing IDO-1 mRNA, with downstream immuno-protective effects (Bando et al., 2019). IDO-1 activation results in degradation of tryptophan which is required for T-cell activation (Gostner, Becker, Überall, et al., 2015; van Baren & Van den Eynde, 2015; Zamanakou, 2007 #498; Zamanakou et al., 2007) but also for *T. gondii* intracellular growth (Pfefferkorn et al., 1986). Latency is maintained not only through CD8<sup>+</sup> T cell IFN- $\gamma$  production, but also by induction of interferon-stimulated genes (ISGs) that enhance immune suppression, although exact mechanisms for disrupting *T. gondii* infection through these genes are unknown (Rinkenberger et al., 2021). Others have observed lower levels of these cytokines during pregnancy with *Toxoplasma* infection. In a study of Brazilian pregnant women, those with chronic *T. gondii* infection had lower levels of IFN- $\gamma$ , TNF- $\alpha$ , and nitrite (Marchioro et al., 2018). A similar observation was made in the U.S. (Pernas et al., 2014). These researchers found 23 lower cytokine levels in U.S. pregnant chronically infected women. The ability of *T. gondii* to produce host immune suppression is well known (Káková et al., 2010), and one mechanism is by the parasite inducing immune cell microRNAs (de Faria Junior et al., 2021). MicroRNAs act on messenger RNA, resulting in degradation or repressing mRNA translation, resulting in less effective inflammatory responses.

The reduction in circulating cytokines could also reflect loss of recognition and effector functions in certain T cell populations, including reduced IFN- $\gamma$  production by CD4<sup>+</sup> and CD8<sup>+</sup> T cells during chronic infection such as the population in this study. Chronic exposure of T cell receptors (TCR) responding over long periods of time to persistent *T. gondii* antigen stimulation may exacerbate the T cell exhaustion seen in pregnancy (Slutsky et al., 2019). T cell exhaustion is marked by increased expression of inhibitory receptors, loss of the ability to secrete cytokines, and development of a different transcriptional program (Catakovic et al., 2017). If CD4<sup>+</sup> T cell exhaustion occurs over the time of *T. gondii* infection, and is combined with pregnancy related T cell alterations, such as reduced levels of IFN- $\gamma$ , the Th-17/Treg balance may shift towards excessive dampening of the effector immune response, so that low grade parasitemia may occur (Khan & Moretto, 2022). Excessive fetal antigen exposure at the placenta also can produce T cell exhaustion, with greater risk associated with older age (Catakovic et al., 2017). T reg function is also important in pregnancy as these cells regulate the CD8<sup>+</sup> effector T cells, and maintain tolerance, but little is known about their role in *T. gondii* infection. Miscarriage in *T. gondii* seropositive women is associated with reduced T reg numbers (Koucký et al., 2014). We found that TNF- $\alpha$  differed from the other cytokines in that it was present at higher plasma concentrations in the *T. gondii* seropositive women. This cytokine is largely produced by macrophages (Parameswaran & Patial, 2010) so this innate immune branch may be more active in the chronically infected women.

In our sample, *T. gondii* positive women had a significantly higher number of miscarriages ( $p=0.008$ ). At the uterus, inflammatory signals are necessary preparation for labor, and if inadequate may influence the natural progression of the pregnancy. These T cell related dynamics need to be explored further in chronic *T. gondii* infection and pregnancy. We have recently published our findings of both increased preterm birth and small for gestational age

infants in the chronic *T. gondii* positive women in the study (Mutka et al., 2022). The role of these immune differences in adverse pregnancy outcomes represents a future challenge.

Our metabolic findings are in line with previous observations showing generally decreasing tryptophan levels and an increasing kynurenine to tryptophan ratio over the course of pregnancy (Schröcksnadel et al., 1996) (Schröcksnadel et al., 2003). (Savitz, 2020) (Cervenka et al., 2017) (Jenny et al., 2011) (Wang et al., 2010). Tryptophan catabolism stands at the crossroads of multiple metabolic, neuroendocrine, and immune processes (Gostner, Becker, Ueberall, et al., 2015). IDO-1 is primarily induced by IFN- $\gamma$  (Duan et al., 2018). The first stable product of IDO-1 enzymatic action is kynurenine, and activity of the IDO-1 enzyme may be estimated by the ratio of kynurenine to tryptophan, in the presence of other markers of immune activation such as neopterin (Fuchs 1990), which is elevated in pregnancy. Neopterin synthesis occurs in activated macrophages and dendritic cells (Mangge et al., 2014), is a marker of immune system activation (Murr et al., 2002) and increases across pregnancy, as was observed in our data, but did not differ by *T. gondii* positivity. Kynurenine downstream metabolites are involved in downregulating inflammation, immune function, and neurotransmission and their ratios and concentrations are carefully regulated in health but can be toxic under conditions of activated immunity (Song et al., 2017). The drop in tryptophan across pregnancy was less pronounced in *T. gondii* seropositive women compared to seronegative individuals suggesting less activation of IDO-1. Shunting of tryptophan into the kynurenine pathway is thought to play a large protective role in infection, perhaps by decreasing the availability of this essential amino acid required by infecting pathogens. Tryptophan can also decline due to low dietary intake or increased metabolic demand, which can occur in pregnancy (Duan et al., 2018). The lower kynurenine/tryptophan ratio observed in the *T. gondii* seropositive women suggests that there may be less functional kynurenine pathway catabolites in *T. gondii* pregnancy.

Further evidence for a reduction in IDO-1 activity in the *T. gondii* positive women is the higher levels of nitrite in the seropositive women. Nitrite is an oxygenated derivative of nitric oxide (NO) and plasma levels could reflect diet (Mattila et al., 2020) or cellular production of NO, a metabolite with a very short plasma half-life (minutes) (Ignarro, 1990). NO levels rise during pregnancy (Sutton et al., 2020) and inducible NOS (iNOS) is a major factor in maintaining a low resistance placental vascular circuit (Zullino et al., 2018). High levels of NO can inhibit IDO-1 mediated tryptophan degradation, and vice versa, thus suppressing the shunting of tryptophan to kynurenine (López et al., 2006; Samelson-Jones & Yeh, 2006).

The lower IgG titers across pregnancy compared to the postpartum may support a more general immune suppression during pregnancy. These data suggest that chronic *T. gondii* infection may impact the normal metabolic and immune characteristics of pregnancy. Our recent report of increased risks for preterm births, miscarriages and small for gestational age infants in chronically infected women suggests that further investigations into immune and metabolic changes in chronicity during pregnancy deserve further study (Mutka T. & Jacques A, 2023). In addition, we have preliminary evidence for different cytokine patterns over time in *T. gondii* seropositive women who gave birth preterm.

## Limitations

All the measurements in the study may have been affected by the hemodilution effects of plasma volume expansion during pregnancy, but this would be a consistent effect across all measures. While our sample size was large and data were collected prospectively, we did not have a non-Hispanic control group or non-pregnant control groups. Many more women born outside the US were *T. gondii* positive (N=148) compared to U.S. born (N=10) in our sample. There were likely many cultural, microbial, and dietary differences that could impact infection, metabolism, and immunity by women born or raised in other countries, but we could not control these many variables. Our population consisted of economically disadvantaged, immigrant women and may not, therefore, be generalizable to populations not experiencing the stresses encountered uniquely in this population.

## Acknowledgements:

Bradley Kane and Tina Mutka for laboratory analyses; participants; Research Nurses; NIH grant R01 HD086805

## References

- Badawy AA (2015, Sep 17). Tryptophan metabolism, disposition and utilization in pregnancy. *Biosci Rep*, 35(5). 10.1042/bsr20150197
- Bando H, Lee Y, Sakaguchi N, Pradipta A, Sakamoto R, Tanaka S, Ma JS, Sasai M, & Yamamoto M (2019). Toxoplasma Effector GRA15-Dependent Suppression of IFN- $\gamma$ -Induced Antiparasitic Response in Human Neurons. *Front Cell Infect Microbiol*, 9, 140. 10.3389/fcimb.2019.00140 [PubMed: 31119110]
- Bathke AC, Schabenberger O, Tobias RD, & Madden LV (2009, 2009/08/01). Greenhouse-Geisser Adjustment and the ANOVA-Type Statistic: Cousins or Twins? *The American Statistician*, 63(3), 239–246. 10.1198/tast.2009.08187
- Beazley DM, & Egerman RS (1998, Aug). Toxoplasmosis. *Semin Perinatol*, 22(4), 332–338. 10.1016/s0146-0005(98)80022-0 [PubMed: 9738998]
- Catakovic K, Klieser E, Neureiter D, & Geisberger R (2017, Jan 5). T cell exhaustion: from pathophysiological basics to tumor immunotherapy. *Cell Commun Signal*, 15(1), 1. 10.1186/s12964-016-0160-z [PubMed: 28073373]
- Cervenka I, Agudelo LZ, & Ruas JL (2017, Jul 28). Kynurenes: Tryptophan's metabolites in exercise, inflammation, and mental health. *Science*, 357(6349). 10.1126/science.aaf9794
- de Faria Junior GM, Murata FHA, Lorenzi HA, Castro BBP, Assoni LCP, Ayo CM, Brandão CC, & de Mattos LC (2021). The Role of microRNAs in the Infection by *T. gondii* in Humans. *Front Cell Infect Microbiol*, 11, 670548. 10.3389/fcimb.2021.670548 [PubMed: 34055667]
- de-la-Torre A, Sauer A, Pfaff AW, Bourcier T, Brunet J, Speeg-Schatz C, Ballonzoli L, Villard O, Ajzenberg D, Sundar N, Grigg ME, Gomez-Marin JE, & Candolfi E (2013, Nov). Severe South American ocular toxoplasmosis is associated with decreased Ifn-gamma/Il-17a and increased Il-6/Il-13 intraocular levels. *PLoS Negl Trop Dis*, 7(11), e2541. 10.1371/journal.pntd.0002541 [PubMed: 24278490]
- Deshmukh AS, Gurupwar R, Mitra P, Aswale K, Shinde S, & Chaudhari S (2021, Mar). *Toxoplasma gondii* induces robust humoral immune response against cyst wall antigens in chronically infected animals and humans. *Microb Pathog*, 152, 104643. 10.1016/j.micpath.2020.104643 [PubMed: 33232762]
- Duan KM, Ma JH, Wang SY, Huang Z, Zhou Y, & Yu H (2018, Jun). The role of tryptophan metabolism in postpartum depression. *Metab Brain Dis*, 33(3), 647–660. 10.1007/s11011-017-0178-y [PubMed: 29307018]

- Dubey JP, Murata FHA, Cerqueira-Cézar CK, Kwok OCH, & Villena I (2021, Oct). Congenital toxoplasmosis in humans: an update of worldwide rate of congenital infections. *Parasitology*, 148(12), 1406–1416. 10.1017/s0031182021001013 [PubMed: 34254575]
- Geisler S, Mayersbach P, Becker K, Schennach H, Fuchs D, & Gostner JM (2015). Serum tryptophan, kynurenine, phenylalanine, tyrosine and neopterin concentrations in 100 healthy blood donors. *Pteridines*, 26, 31 – 36.
- Gostner JM, Becker K, Überall F, & Fuchs D (2015, May). The potential of targeting indoleamine 2,3-dioxygenase for cancer treatment. *Expert Opin Ther Targets*, 19(5), 605–615. 10.1517/14728222.2014.995092 [PubMed: 25684107]
- Gostner JM, Becker K, Ueberall F, & Fuchs D (2015, Jun). The good and bad of antioxidant foods: An immunological perspective. *Food Chem Toxicol*, 80, 72–79. 10.1016/j.fct.2015.02.012 [PubMed: 25698357]
- Hjortsø MD, Larsen SK, Kongsted P, Met Ö, Frøsig TM, Andersen GH, Ahmad SM, Svane IM, Becker JC, Straten PT, & Andersen MH (2015, Jan). Tryptophan 2,3-dioxygenase (TDO)-reactive T cells differ in their functional characteristics in health and cancer. *Oncoimmunology*, 4(1), e968480. 10.4161/21624011.2014.968480 [PubMed: 25949861]
- Hotez PJ (2014, Sep). Neglected parasitic infections and poverty in the United States. *PLoS Negl Trop Dis*, 8(9), e3012. 10.1371/journal.pntd.0003012 [PubMed: 25188455]
- Ignarro LJ (1990, Nov). Nitric oxide. A novel signal transduction mechanism for transcellular communication. *Hypertension*, 16(5), 477–483. 10.1161/01.hyp.16.5.477 [PubMed: 1977698]
- Jenny M, Klieber M, Zaknun D, Schroecksadel S, Kurz K, Ledochowski M, Schennach H, & Fuchs D (2011, Feb). In vitro testing for anti-inflammatory properties of compounds employing peripheral blood mononuclear cells freshly isolated from healthy donors. *Inflamm Res*, 60(2), 127–135. 10.1007/s00011-010-0244-y [PubMed: 20740299]
- Ka ková S, Holá V, Zajíčková A, Kodym P, & Flegr J (2010, Nov). Modulation of immunity in mice with latent toxoplasmosis--the experimental support for the immunosuppression hypothesis of Toxoplasma-induced changes in reproduction of mice and humans. *Parasitol Res*, 107(6), 1421–1427. 10.1007/s00436-010-2013-9 [PubMed: 20721578]
- Khan IA, & Moretto M (2022, Aug). Immune responses to *Toxoplasma gondii*. *Curr Opin Immunol*, 77, 102226. 10.1016/j.coi.2022.102226 [PubMed: 35785567]
- Kodym P, Malý M, Beran O, Jilich D, Rozsypal H, Machala L, & Holub M (2015, Feb). Incidence, immunological and clinical characteristics of reactivation of latent *Toxoplasma gondii* infection in HIV-infected patients. *Epidemiol Infect*, 143(3), 600–607. 10.1017/s0950268814001253 [PubMed: 24850323]
- Kong JT, Grigg ME, Uyetake L, Parmley S, & Boothroyd JC (2003, May 1). Serotyping of *Toxoplasma gondii* infections in humans using synthetic peptides. *J Infect Dis*, 187(9), 1484–1495. 10.1086/374647 [PubMed: 12717631]
- Koucký M, Malí ková K, Cindrová-Davies T, Germanová A, Pa ízek A, Kalousová M, Hájek Z, & Zima T (2014, Dec). Low levels of circulating T-regulatory lymphocytes and short cervical length are associated with preterm labor. *J Reprod Immunol*, 106, 110–117. 10.1016/j.jri.2014.04.001 [PubMed: 24855050]
- Kudo Y, Boyd CA, Spyropoulou I, Redman CW, Takikawa O, Katsuki T, Hara T, Ohama K, & Sargent IL (2004, Apr). Indoleamine 2,3-dioxygenase: distribution and function in the developing human placenta. *J Reprod Immunol*, 61(2), 87–98. 10.1016/j.jri.2003.11.004 [PubMed: 15063632]
- Lima TS, & Lodoen MB (2019). Mechanisms of Human Innate Immune Evasion by *Toxoplasma gondii*. *Front Cell Infect Microbiol*, 9, 103. 10.3389/fcimb.2019.00103 [PubMed: 31041194]
- López AS, Alegre E, Díaz A, Mugueta C, & González A (2006, Aug 15). Bimodal effect of nitric oxide in the enzymatic activity of indoleamine 2,3-dioxygenase in human monocytic cells. *Immunol Lett*, 106(2), 163–171. 10.1016/j.imlet.2006.05.008 [PubMed: 16797727]
- Mangge H, Becker K, Fuchs D, & Gostner JM (2014, Jun 26). Antioxidants, inflammation and cardiovascular disease. *World J Cardiol*, 6(6), 462–477. 10.4330/wjc.v6.i6.462 [PubMed: 24976919]


- Manuel L, Santos-Gomes G, & Noormahomed EV (2020, Nov 11). Human toxoplasmosis in Mozambique: gaps in knowledge and research opportunities. *Parasit Vectors*, 13(1), 571. 10.1186/s13071-020-04441-3 [PubMed: 33176884]
- Marchioro AA, Colli CM, de Souza CZ, da Silva SS, Tiyo BT, Evangelista FF, Higa L, Conchon-Costa I, & Falavigna-Guilherme AL (2018, Jun). Analysis of cytokines IFN- $\gamma$ , TNF- $\alpha$ , TGF- $\beta$  and nitric oxide in amniotic fluid and serum of pregnant women with toxoplasmosis in southern Brazil. *Cytokine*, 106, 35–39. 10.1016/j.cyto.2018.02.023 [PubMed: 29549721]
- Mattila M, Niinistö S, Takkinen HM, Tapanainen H, Reinivuo H, Åkerlund M, Suomi J, Ahonen S, Ilonen J, Toppari J, Knip M, Veijola R, & Virtanen SM (2020, Nov 19). Maternal Nitrate and Nitrite Intakes during Pregnancy and Risk of Islet Autoimmunity and Type 1 Diabetes: The DIPP Cohort Study. *J Nutr*, 150(11), 2969–2976. 10.1093/jn/nxaa250 [PubMed: 32856042]
- Moldenhauer LM, Hull ML, Foyle KL, McCormack CD, & Robertson SA (2022, Oct 15). Immune-Metabolic Interactions and T Cell Tolerance in Pregnancy. *J Immunol*, 209(8), 1426–1436. 10.4049/jimmunol.2200362 [PubMed: 36192117]
- Montoya JG, & Liesenfeld O (2004, Jun 12). Toxoplasmosis. *Lancet*, 363(9425), 1965–1976. 10.1016/s0140-6736(04)16412-x [PubMed: 15194258]
- Motulsky HJ, & Brown RE (2006, Mar 9). Detecting outliers when fitting data with nonlinear regression - a new method based on robust nonlinear regression and the false discovery rate. *BMC Bioinformatics*, 7, 123. 10.1186/1471-2105-7-123 [PubMed: 16526949]
- Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, Brown C, & Mellor AL (1998, Aug 21). Prevention of allogeneic fetal rejection by tryptophan catabolism. *Science*, 281(5380), 1191–1193. 10.1126/science.281.5380.1191 [PubMed: 9712583]
- Murr C, Widner B, Wirleitner B, & Fuchs D (2002, Apr). Neopterin as a marker for immune system activation. *Curr Drug Metab*, 3(2), 175–187. 10.2174/1389200024605082 [PubMed: 12003349]
- Mutka T, S. A, Yoo JY, , Dutra SOV., Ji M, Louis-, & Jacques A, B. K, Prescott S, Kim K , Groer M. (2023). Adverse pregnancy outcomes in *Toxoplasma gondii* seropositive Hispanic women. *The Journal of Obstetrics and Gynaecology Research*, *in press*.
- Mutka T, Seyfang A, Yoo JY, Dutra SVO, Ji M, Louis-Jacques A, Bruder K, Prescott S, Kim K, & Groer M (2022, Dec 10). Adverse pregnancy outcomes in *Toxoplasma gondii* seropositive Hispanic women. *J Obstet Gynaecol Res*. 10.1111/jog.15511
- Nayeri T, Sarvi S, Moosazadeh M, Amouei A, Hosseini Z, & Daryani A (2020, Mar). The global seroprevalence of anti-*Toxoplasma gondii* antibodies in women who had spontaneous abortion: A systematic review and meta-analysis. *PLoS Negl Trop Dis*, 14(3), e0008103. 10.1371/journal.pntd.0008103 [PubMed: 32168351]
- Pappas G, Roussos N, & Falagas ME (2009, Oct). Toxoplasmosis snapshots: global status of *Toxoplasma gondii* seroprevalence and implications for pregnancy and congenital toxoplasmosis. *Int J Parasitol*, 39(12), 1385–1394. 10.1016/j.ijpara.2009.04.003 [PubMed: 19433092]
- Parameswaran N, & Patial S (2010). Tumor necrosis factor- $\alpha$  signaling in macrophages. *Crit Rev Eukaryot Gene Expr*, 20(2), 87–103. 10.1615/critrevueukargeneexpr.v20.i2.10 [PubMed: 21133840]
- Pernas L, Ramirez R, Holmes TH, Montoya JG, & Boothroyd JC (2014, Sep 15). Immune profiling of pregnant *Toxoplasma*-infected US and Colombia patients reveals surprising impacts of infection on peripheral blood cytokines. *J Infect Dis*, 210(6), 923–931. 10.1093/infdis/jiu189 [PubMed: 24664173]
- Pfefferkorn ER, Eckel M, & Rebhun S (1986, Sep). Interferon-gamma suppresses the growth of *Toxoplasma gondii* in human fibroblasts through starvation for tryptophan. *Mol Biochem Parasitol*, 20(3), 215–224. 10.1016/0166-6851(86)90101-5 [PubMed: 3093859]
- Piccinni MP, Raghupathy R, Saito S, & Szekeres-Bartho J (2021). Cytokines, Hormones and Cellular Regulatory Mechanisms Favoring Successful Reproduction. *Front Immunol*, 12, 717808. 10.3389/fimmu.2021.717808 [PubMed: 34394125]
- Rezende-Oliveira K, Gómez-Hernández C, da Silva MV, Helmo FR, & Rodrigues V (2020, Jun). Analysis of regulatory T cells and CTLA-4 expression in pregnant women according to seropositivity to *Toxoplasma gondii*. *Parasitology*, 147(7), 810–815. 10.1017/s0031182020000475 [PubMed: 32183924]



- Rinkenberger N, Abrams ME, Matta SK, Schoggins JW, Alto NM, & Sibley LD (2021, Dec 6). Overexpression screen of interferon-stimulated genes identifies RARRES3 as a restrictor of *Toxoplasma gondii* infection. *Elife*, 10. 10.7554/eLife.73137
- Roiko MS, LaFavers K, Leland D, & Arrizabalaga G (2018, Mar). *Toxoplasma gondii*-positive human sera recognise intracellular tachyzoites and bradyzoites with diverse patterns of immunoreactivity. *Int J Parasitol*, 48(3–4), 225–232. 10.1016/j.ijpara.2017.08.016 [PubMed: 29170086]
- Saeij JP, Collier S, Boyle JP, Jerome ME, White MW, & Boothroyd JC (2007, Jan 18). *Toxoplasma* co-opts host gene expression by injection of a polymorphic kinase homologue. *Nature*, 445(7125), 324–327. 10.1038/nature05395 [PubMed: 17183270]
- Samelson-Jones BJ, & Yeh SR (2006, Jul 18). Interactions between nitric oxide and indoleamine 2,3-dioxygenase. *Biochemistry*, 45(28), 8527–8538. 10.1021/bi060143j [PubMed: 16834326]
- Sana M, Rashid M, Rashid I, Akbar H, Gomez-Marin JE, & Dimier-Poisson I (2022, Jan-Dec). Immune response against toxoplasmosis-some recent updates RH: *Toxoplasma gondii* immune response. *Int J Immunopathol Pharmacol*, 36, 3946320221078436. 10.1177/03946320221078436 [PubMed: 35227108]
- Sasai M, Pradipta A, & Yamamoto M (2018, Mar 10). Host immune responses to *Toxoplasma gondii*. *Int Immunol*, 30(3), 113–119. 10.1093/intimm/dxy004 [PubMed: 29408976]
- Savitz J (2020, Jan). The kynurenine pathway: a finger in every pie. *Mol Psychiatry*, 25(1), 131–147. 10.1038/s41380-019-0414-4 [PubMed: 30980044]
- Schröcksnadel H, Baier-Bitterlich G, Dapunt O, Wachter H, & Fuchs D (1996, Jul). Decreased plasma tryptophan in pregnancy. *Obstet Gynecol*, 88(1), 47–50. 10.1016/0029-7844(96)00084-1 [PubMed: 8684760]
- Schröcksnadel K, Widner B, Bergant A, Neurauter G, Schennach H, Schröcksnadel H, & Fuchs D (2003, Jan 3). Longitudinal study of tryptophan degradation during and after pregnancy. *Life Sci*, 72(7), 785–793. 10.1016/s0024-3205(02)02304-4 [PubMed: 12479977]
- Sedlmayr P, Blaschitz A, & Stocker R (2014). The role of placental tryptophan catabolism. *Front Immunol*, 5, 230. 10.3389/fimmu.2014.00230 [PubMed: 24904580]
- Shapira S, Harb OS, Caamano J, & Hunter CA (2004, Mar 9). The NF-kappaB signaling pathway: immune evasion and immunoregulation during toxoplasmosis. *Int J Parasitol*, 34(3), 393–400. 10.1016/j.ijpara.2003.12.005 [PubMed: 15055212]
- Shobab L, Pleyer U, Johnsen J, Metzner S, James ER, Torun N, Fay MP, Liesenfeld O, & Grigg ME (2013, Nov 1). *Toxoplasma* serotype is associated with development of ocular toxoplasmosis. *J Infect Dis*, 208(9), 1520–1528. 10.1093/infdis/jit313 [PubMed: 23878321]
- Silvano A, Seravalli V, Strambi N, Cecchi M, Tartarotti E, Parenti A, & Di Tommaso M (2021, Sep). Tryptophan metabolism and immune regulation in the human placenta. *J Reprod Immunol*, 147, 103361. 10.1016/j.jri.2021.103361 [PubMed: 34365162]
- Slutsky R, Romero R, Xu Y, Galaz J, Miller D, Done B, Tarca AL, Gregor S, Hassan SS, Leng Y, & Gomez-Lopez N (2019). Exhausted and Senescent T Cells at the Maternal-Fetal Interface in Preterm and Term Labor. *J Immunol Res*, 2019, 3128010. 10.1155/2019/3128010 [PubMed: 31263712]
- Song P, Ramprasath T, Wang H, & Zou MH (2017, Aug). Abnormal kynurenine pathway of tryptophan catabolism in cardiovascular diseases. *Cell Mol Life Sci*, 74(16), 2899–2916. 10.1007/s00018-017-2504-2 [PubMed: 28314892]
- Sutton EF, Gemmel M, & Powers RW (2020, Feb 1). Nitric oxide signaling in pregnancy and preeclampsia. *Nitric Oxide*, 95, 55–62. 10.1016/j.niox.2019.11.006 [PubMed: 31852621]
- Suzuki Y (2021, Apr). A pathway to cure chronic infection with *Toxoplasma gondii* through immunological intervention. *Parasitol Int*, 81, 102259. 10.1016/j.parint.2020.102259 [PubMed: 33271362]
- Tatsumi K, Higuchi T, Fujiwara H, Nakayama T, Egawa H, Itoh K, Fujii S, & Fujita J (2000, Jul 21). Induction of tryptophan 2,3-dioxygenase in the mouse endometrium during implantation. *Biochem Biophys Res Commun*, 274(1), 166–170. 10.1006/bbrc.2000.3115 [PubMed: 10903913]
- van Baren N, & Van den Eynde BJ (2015, Sep). Tumoral Immune Resistance Mediated by Enzymes That Degrade Tryptophan. *Cancer Immunol Res*, 3(9), 978–985. 10.1158/2326-6066.Cir-15-0095 [PubMed: 26269528]




- Wang Y, Liu H, McKenzie G, Witting PK, Stasch JP, Hahn M, Changsirivathanathamrong D, Wu BJ, Ball HJ, Thomas SR, Kapoor V, Celermajer DS, Mellor AL, Keaney JF Jr., Hunt NH, & Stocker R (2010, Mar). Kynurenine is an endothelium-derived relaxing factor produced during inflammation. *Nat Med*, 16(3), 279–285. 10.1038/nm.2092 [PubMed: 20190767]
- Weilhammer DR, Iavarone AT, Villegas EN, Brooks GA, Sinai AP, & Sha WC (2012, Sep). Host metabolism regulates growth and differentiation of *Toxoplasma gondii*. *Int J Parasitol*, 42(10), 947–959. 10.1016/j.ijpara.2012.07.011 [PubMed: 22940576]
- Xiao J, & Yolken RH (2015, Apr). Strain hypothesis of *Toxoplasma gondii* infection on the outcome of human diseases. *Acta Physiol (Oxf)*, 213(4), 828–845. 10.1111/apha.12458 [PubMed: 25600911]
- Zamanakou M, Germeis AE, & Karanikas V (2007, Aug 15). Tumor immune escape mediated by indoleamine 2,3-dioxygenase. *Immunol Lett*, 111(2), 69–75. 10.1016/j.imlet.2007.06.001 [PubMed: 17644189]
- Zimmermann S, Murray PJ, Heeg K, & Dalpke AH (2006, Feb 1). Induction of suppressor of cytokine signaling-1 by *Toxoplasma gondii* contributes to immune evasion in macrophages by blocking IFN-gamma signaling. *J Immunol*, 176(3), 1840–1847. 10.4049/jimmunol.176.3.1840 [PubMed: 16424215]
- Zullino S, Buzzella F, & Simoncini T (2018, Nov). Nitric oxide and the biology of pregnancy. *Vascul Pharmacol*, 110, 71–74. 10.1016/j.vph.2018.07.004 [PubMed: 30076925]




**Figure 1. Biogenic amines and their metabolites**

*IDO*, indolamine 2,3-dioxygenase; *TDO*, tryptophan 2,3-dioxygenase; *KAT*, kynurenine aminotransferase; *KMO*, kynurenine 3-monoxygenase; *KYNU*, kynureninase; *QPRT*, quinolinate phosphoribosyltransferase; *NAD*, nicotinamide adenine dinucleotide; *BH4*, tetrahydrobiopterin; *TPH*, tryptophan hydroxylase; *NOS*, nitric oxide synthase; *GTP*, guanosine triphosphate; *GTPCH*, GTP cyclohydrolase; *PAH*, phenylalanine hydroxylase; *ThH*, tyrosine hydroxylase.




**Figure 2. Plasma tryptophan levels were higher across pregnancy in the seropositive women** After outliers at each timepoint were removed by robust nonlinear regression and false discovery rate (ROUT,  $q=1\%$ ), mixed effects modeling revealed significantly increased tryptophan levels across ( $F=39.89$ ,  $p<0.001$ ) and by *T. gondii* seropositive status ( $F=7.969$ ,  $p<0.005$ ), interaction ns.




**Figure 3. Kynurenine Tryptophan ratio rises throughout pregnancy, but trended lower in *T.gondii* positive women**

After outliers at each timepoint were removed by robust nonlinear regression and false discovery rate (ROUT,  $q=1\%$ ), mixed effects modeling revealed that the kynurenine to tryptophan ratio rose over pregnancy ( $F=10.57$ ,  $p=0.0013$ ) indicating more conversion of tryptophan to kynurenine in later pregnancy, and *T. gondii* seropositive women had a trend towards lower ratios across pregnancy ( $F=3.814$ ,  $p=0.052$ ), interaction ns.



**Figure 4. Plasma Nitrite levels were higher across pregnancy in *T. gondii* seropositive women** After outliers at each timepoint were removed by robust nonlinear regression and false discovery rate (ROUT,  $q=1\%$ ), mixed effects modeling revealed that nitrite rose in both groups through pregnancy ( $F=9.36$ ,  $p<0.001$ ) and was significantly higher across time in the *T. gondii* positive group ( $F=7.4$ ,  $p=0.007$ ), interaction ns.



**Figure 5. Cytokines across pregnancy by *T.gondii* status**

After outliers at each timepoint were removed by robust nonlinear regression and false discovery rate (ROUT,  $q=1\%$ ), mixed effects modeling revealed that, 5a) IFN- $\gamma$  varied significantly over time ( $F= 3.45, p=0.005,$ ) and was lower in *T.gondii* positive pregnant women ( $F= 25.95, p<0.001$ ); 5b). IL-6 increased over time ( $F = 14.27, p<0.001,$  and was lower in *T. gondii* positive women  $F=8.44, p=0.004$ ; 5c) IL-17 varied significantly over time ( $F = 9.71, p<0.001,$  but was lower in *T.gondii* women  $F=8.44, p=0.004$ ; 5d) IL-12 varied significantly over time ( $F = 8.406, p<0.001,$  and was lower in *T. gondii* women  $F=10.7, p=0.0012$ . 5e). 5f), TNF- $\alpha$ , showed significant increases across time ( $F = 9.835, p< 0.001,$  and by *T. gondii* status  $F=8.07, p<0.001$  (Figure 5f). Interactions of time and cytokines ns except IL12 ( $F=6236 P<0.001$ ).



**Table 1.**

Demographic variables by *T. gondii* seropositivity status.

	<i>T. gondii</i> negative	<i>T. gondii</i> positive	<i>P</i> value								
Number of Women	131	158									
Maternal Age (mean, range)	30.7(19-45)	32.2 (18-47)	0.033*								
<b>Country of Birth</b>			0.000***								
United States	40	10									
Puerto Rico	18	8									
Mexico	50	58									
Dominican Republic	4	8									
Cuba	4	21									
Honduras	7	23									
Guatemala	5	14									
Other	3	16									
Number of pregnancies (mean, range)	3 (1-9)	4 (1-15)	0.111								
Maternal BMI at visit 1 (mean, range)	30.6 (19-56)	31.4 (21-57)	0.160								
<b>Marital Status</b>			0.100								
Single/unmarried	76	81									
Married	49	59									
Divorced/Separated	6	18									
<b>Education</b>			0.073								
Grammar school	4	5									
Middle school	25	53									
High school graduate	74	69									
College graduate	26	27									
Postgraduate	2	4									
<b>Income</b>			0.041*								
<\$4,999	25	31									
\$5,000-\$14,999	22	43									
\$15,000-\$24,999	45	60									
\$25,000-\$39,000	21	16									
\$40,000-\$69,000	13	5									
\$70,000+	1	3									
Toxoplasma gondii serotype		<table border="1"> <tr> <td>Type I/III</td> <td>31 (20%)</td> </tr> <tr> <td>Type II</td> <td>25 (16%)</td> </tr> <tr> <td>atypical</td> <td>41 (26%)</td> </tr> <tr> <td>nonreactive</td> <td>60 (38%)</td> </tr> </table>	Type I/III	31 (20%)	Type II	25 (16%)	atypical	41 (26%)	nonreactive	60 (38%)	
Type I/III	31 (20%)										
Type II	25 (16%)										
atypical	41 (26%)										
nonreactive	60 (38%)										
Infant weight in kg (mean, range)	3.39 (.91-4.8)	3.19 (0.4-4.6)	0.093								
Gestational Age at Delivery in weeks (meann, range)	38.2 (23-41.1)	37.3 (21.4-41)	0.085								
Miscarriage	2	14	0.008**								
Preterm Birth (excluding miscarriage)	17	30	0.198								

	<b>T. gondii negative</b>	<b>T. gondii positive</b>	<b>P value</b>
Preeclampsia	10	7	0.453
Gestational diabetes	19	28	0.266

Chi Square or t-test analyses: \*p<0.05; \*\*p <0.01, \*\*\*p<0.001. Data are given as means with ranges or as percentages

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript